Antibodies and related products are the fastest growing class of therapeutic agents. By analysing the regulatory approvals of IgG-based biotherapeutic agents in the past 10 years, we can gain ...

New data showed that Bimzelx sustained disease control of hidradenitis suppurativa up to 2 years, UCB announced in a press release.“As the first presentation of [Bimzelx (bimekizumab)] data this year, ...

TEPEZZA, as the first FDA-approved treatment for thyroid eye disease, marks a major breakthrough in managing TED, addressing a critical medical gap for patients who have long had few treatment ...

Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...

New 2-year data show the long-term effects of bimekizumab on hidradenitis suppurativa, indicating its potential as a valuable ...

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of ...